What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?

Author(s): G. Spada*, G.V. Vighi, S. Pagani, G.D. Vighi, M. Venegoni, M. Ruocco.

Journal Name: Current Drug Safety

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Introduction: Oral anticoagulants, including vitamin K inhibitors (VKAs) and direct anticoagulants (DOACs) are important for preventing and treating thromboembolic diseases. However, they are not recommended for use in all patients due to negative side effects and adverse drug reactions (ADRs). Currently, there is a paucity of information about their use in real life. Therefore, the aim of this pilot study is to report on the rate of serious ADRs in oral anticoagulant users, determine patient characteristics associated with increased risk of ADRs, and identify possible management strategies for reducing risk of ADRs within a hospital setting.

Methods: Patients admitted to the Internal Medicine Department of the Vimercate Hospital were recruited between November 1, 2015 and October 31, 2016. All patients reporting an ADR associated with anticoagulant use were selected. Demographic, clinical, and observational data were extracted from electronic hospital records, in particular, by the hospital discharge letters and other clinical records. The main outcome of the study was to evaluate the incidence of anticoagulants serious adverse drug reactions conditioning hospital admission, the percentage of preventable reactions, and the determinants of those.

Results and Discussion: Of the 2,064 admissions, 102 (4.9%) eligible patients were identified. Age ranged from 60-95 years (mean = 81.9, standard deviation = 6,59) and 47.1% (n=48) were female. Of the 102 cases, 68 used VKAs and 34 used DOACs. The most common admission diagnosis was heart failure following anemia or hemorrhage (56 cases), followed by acute hemorrhage (with or without anemia; 29 cases), and anemia not associated with evident hemorrhage (17cases). The majority of VKA users (n=65, 95.6%) had a high risk of major bleeding. ADRs were found to be preventable in 96% of VKA users and 68% of DOACs users.

Conclusion: This study highlights the large percentage of ADRs from oral anticoagulants that can be avoided with more careful patient management. Periodic check-up of cardiac and renal function, as well as blood count, may be useful for reducing the risk of ADRs, especially in older DOACs users. Further research is needed to get new data to improve the patients monitoring system.

Keywords: Oral anticoagulants, vitamin K inhibitors, hemorrhage, direct anticoagulants, glomerular filtrate rate, anemia, electronic hospital records.

[1]
Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63(4): 321-8.
[http://dx.doi.org/10.1016/j.jacc.2013.07.104] [PMID: 24076487]
[2]
Khan F, Huang H, Datta YH. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis 2016; 42(4): 573-8.
[http://dx.doi.org/10.1007/s11239-016-1410-z] [PMID: 27520093]
[3]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[4]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[5]
Saraf K, Morris PD, Garg P, Sheridan P, Storey R. Non-vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations. Postgrad Med J 2014; 90(1067): 520-8.
[http://dx.doi.org/10.1136/postgradmedj-2014-132605] [PMID: 25085900]
[6]
Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016; 388(10046): 806-17.
[http://dx.doi.org/10.1016/S0140-6736(16)31257-0] [PMID: 27560276]
[7]
Raschi E, Bianchin M, De Ponti R, De Ponti F, Ageno W. Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. Pharmacol Res 2017; 120: 206-18.
[http://dx.doi.org/10.1016/j.phrs.2017.03.026] [PMID: 28366835]
[8]
Villines TC, Peacock WF. Safety of direct oral anticoagulants: Insights from postmarketing studies. Am J Emerg Med 2016; 34(11S): 9-13.
[http://dx.doi.org/10.1016/j.ajem.2016.09.047] [PMID: 27697441]
[9]
Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193-203.
[http://dx.doi.org/10.1016/j.blre.2017.02.001] [PMID: 28196633]
[10]
Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at https//www.micromedexsolutions.com.niguarda.clas.cineca.it/ Last access8.3.2019.
[11]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[12]
Perrone V, Conti V, Venegoni M, et al. Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: A retrospective 2-year characterization. Clinicoecon Outcomes Res 2014; 6: 505-14.
[PMID: 25506231]
[13]
Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296(15): 1858-66.
[http://dx.doi.org/10.1001/jama.296.15.1858] [PMID: 17047216]
[14]
Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: A review of recent observational studies. Drug Saf 2015; 38(5): 437-53.
[http://dx.doi.org/10.1007/s40264-015-0281-0] [PMID: 25822400]
[15]
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA 2016; 316(20): 2115-25.
[http://dx.doi.org/10.1001/jama.2016.16201] [PMID: 27893129]
[16]
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538.
[PMID: 10118597]
[17]
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014; 129(23): 2440-92.
[http://dx.doi.org/10.1161/CIR.0000000000000029] [PMID: 24589852]
[18]
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719-47.
[http://dx.doi.org/10.1093/eurheartj/ehs253] [PMID: 22922413]
[19]
Sennesael AL, Larock AS, Devalet B, et al. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: A prospective study. Br J Clin Pharmacol 2018; 84(7): 1544-56.
[http://dx.doi.org/10.1111/bcp.13580] [PMID: 29522647]
[20]
Viprey M, Jeannin R, Piriou V, et al. Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: A multicenter, cross-sectional study. J Clin Pharm Ther 2017; 42(1): 58-63.
[http://dx.doi.org/10.1111/jcpt.12473] [PMID: 27778374]
[21]
Gardarsdottir H. Characterising the risk of major bleeding in patients with Non -Valvular Atrial Fibrillation: Non interventional study of patients taking Direct Anticoagulants in the EU. Available from http://www.encepp.eu/encepp/viewResource.htm?id=28664 Last access on 4 June 2019
[22]
Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause of hospital admissions: A 6-month experience in a single center in Greece. Eur J Intern Med 2008; 19(7): 505-10.
[http://dx.doi.org/10.1016/j.ejim.2007.06.030] [PMID: 19013378]
[23]
Vormfelde SV, Abu Abed M, Hua TD, Schneider S, Friede T, Chenot JF. Educating orally anticoagulated patients in drug safety: A cluster-randomized study in general practice. Dtsch Arztebl Int 2014; 111(37): 607-14.
[PMID: 25283757]
[24]
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf 2006; 29(5): 385-96.
[http://dx.doi.org/10.2165/00002018-200629050-00003] [PMID: 16689555]
[25]
Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 2011; 67(5): 507-19.
[http://dx.doi.org/10.1007/s00228-010-0977-0] [PMID: 21221958]
[26]
Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007; 370(9586): 493-503.
[http://dx.doi.org/10.1016/S0140-6736(07)61233-1] [PMID: 17693178]
[27]
Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial fibrillation in older people: Concepts and controversies. Front Med (Lausanne) 2019; 6: 175.
[http://dx.doi.org/10.3389/fmed.2019.00175] [PMID: 31440508]
[28]
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary. Europace 2018; 20(8): 1231-42.
[http://dx.doi.org/10.1093/europace/euy054] [PMID: 29562331]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [38 - 44]
Pages: 7
DOI: 10.2174/1574886314666191003162104

Article Metrics

PDF: 25
HTML: 4